Merck Settles Class Suit Targeting Coppertone Claims, Denies Wrongdoing
This article was originally published in The Tan Sheet
Merck agrees to pay a maximum of $10 million to consumers to settle class-action case and to comply with labeling and claims regulations that will become law in December for most firms under an FDA final rule. The settlement in federal court resolves separate litigation against Coppertone filed in California state court.
You may also be interested in...
A lawsuit filed in federal court in New Jersey alleges Merck has misrepresented the UV-protective benefits of its Coppertone sunscreen products, subjecting consumers to potential risks.
FDA could exclude increasingly popular spray sunscreens from the final monograph unless firms submit sufficient safety and efficacy data, according to an advanced notice of proposed rulemaking.
Merck stands to pick up the switch rights to the proton pump inhibitor Zegerid at the head of a strong switch program if its planned acquisition of Schering-Plough succeeds